RESUMEN
OBJECTIVE: Chresta martii is broadly used by folk medicine due to its anti-inflammatory effects, but there is a lack of preclinical data on its pharmacological mechanisms. This study investigated the efficacy of Chresta martii ethanolic extract (CEE) in the zymosan-induced temporomandibular joint arthritis (TMJ) and evaluated the possible role of TNF-α, nitric oxide (NO), and heme oxygenase-1 (HO-1). METHODS: Male Wistar rats (160-220 g) were pre-treated with CEE (100, 200 or 400 mg/kg; v.o) 1 h before zymosan injection (2 mg; i.art). Mechanical hypernociception (g) was assessed 4 h later. The trigeminal ganglion was collected for TNF-α quantification (ELISA), total cell count and myeloperoxidase activity (MPO) were assayed in the synovial lavage 6 h after arthritis induction. Additionally, animals were pre-treated with L-NAME (30 mg/kg; i.p.) or ZnPP-IX (3 mg/kg, s.c.) to assess the involvement of NO and HO-1, respectively. RESULTS: CEE 400 mg/kg (v.o) increased (p < 0.05) hypernociception threshold, reduced the cell counts and MPO activity in the synovial lavage, as well as decreased TNF-α levels in the trigeminal ganglion. ZnPP-IX abolished the analgesic effect of CEE, but not L-NAME. CONCLUSION: The anti-inflammatory and antinociceptive effects of CEE depended on the HO-1 pathway integrity and TNF-α suppression.
RESUMEN
Objetivo: Identificar a caracterização do uso do alendronato sódico por pacientes em tratamento para osteoporose na Atenção Primária à Saúde (APS) no município de Sobral, CE, e relacionar os possíveis fatores que poderiam influenciar a adesão ao tratamento medicamentoso. Métodos: Estudo observacional, transversal, descritivo e quantitativo. Foi realizado com o uso de um questionário, entre fevereiro e março de 2012, com 90 pacientes em tratamento para osteoporose com alendronato sódico, de ambos os sexos e maiores de 50 anos. Resultados: Noventa e nove porcento dos pacientes eram representados pelo o sexo feminino. Sobre a faixa etária, 67% correspondiam a mais de 60 anos. Houve predominância de fratura na coluna em 45% dos pacientes. Sessenta e dois porcento ingeriam o alendronato de forma inadequada e 43% relataram alguma reação adversa ao medicamento. Conclusão: O uso inadequado do alendronato de sódio pelos pacientes, assim como sua ausência nos Centros de Saúde da Família (CSF), são fatores que influenciam diretamente na não adesão ao tratamento da osteoporose. É importante que sejam desenvolvidas ações de educação em saúde sobre o uso adequado desse medicamento como forma de garantia de qualidade de vida.
Objective: To examine the use of alendronate sodium among patients undergoing treatment for osteoporosis in primary health care (PHC) in the city of Sobral, CE, and to list the possible factors that could influence adherence to medication. Methods: An observational, cross-sectional, descriptive, and quantitative study was conducted using a questionnaire between February and March 2012. The participants were 90 patients from both sexes being treated with alendronate sodium for osteoporosis, and aged 50 years or more. Results: Of the participants, 99% were females and 67% were more than 60 years old. Spinal fracture was predominant (45% of the sample), 62% consumed the drug inappropriately, and 43% reported an adverse drug reaction. Conclusion: Improper use of alendronate sodium by patients and its shortage in the Family Health Center (FHC) are factors that directly influence adherence to osteoporosis medication. It is important that health education programs be developed on the appropriate use of this drug as a guarantee of quality of life.
Objetivo: Identificar la caracterización del uso de alendronato para los pacientes que reciben tratamiento para la osteoporosis en Atención Primaria de Salud (APS) en el municipio de Sobral-CE, y la lista de los posibles factores que podrían influir en la adherencia a la medicación. Métodos: Se realizó un estudio observacional, transversal, descriptivo y cuantitativo. Se llevó a cabo a través de un cuestionario entre febrero y marzo de 2012, con 90 pacientes tratados con alendronato para la osteoporosis en ambos sexos y mayores de 50 años. Resultados: Noventa y nueve por ciento fueron representados por las mujenes. Entre el grupo de edad, el 67% eran mayores de 60 años. Predominaron fractura vertebral representado por 45%. Sesenta y dos por ciento recibió el fármaco de manera inapropiada y 43% informó una reacción adversa a un medicamento. Conclusión: El uso inadecuado de alendronato por los pacientes, así como su ausencia en el Centro de Salud de la Familia (CSF) son factores que influyen directamente en la falta de adherencia al tratamiento de la osteoporosis. Es importante que se desarrollen actividades educativas de salud sobre el uso adecuado de este fármaco como una garantía de calidad de vida.
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Osteoporosis , Atención Primaria de Salud , Alendronato , Servicios de Salud para AncianosRESUMEN
It is recommended to evaluate the presence of latent tuberculosis infection (LTBI) prior to the use of antitumor necrosis factor α. The aim of this study is to assess the presence of LTBI in patients with rheumatic diseases undergoing treatment with infliximab in an endemic area for tuberculosis (TB). LTBI was searched through the contact history, chest X-ray and tuberculin skin test with purified protein derivative (PPD) ≥5 mm. We studied 157 patients in the period from May 2005 to October 2008, 99 (63.1%) were women with average age of 49 years and 58 (36.9%) were men with average age of 41 years. The group comprising 90 patients (57.3%) with rheumatoid arthritis (RA), 54 (34.4%) with ankylosing spondylitis (AS) and 13 (8.3%) with psoriatic arthritis (PsA) had PPD reactor 13.4% (21/157), being prevented by isoniazid (INH) in these patients. There are dissimilar responsiveness to the PPD between the three pathologies, and the reactivity was lower in RA (RA × AS: χ(2) = 12; P = 0.0004; and RA × PsA: χ(2) with Yates' correction = 3.6; P = 0.05). No significant difference between the reactivity of the PPD and the use of immunosuppressive drugs (P = 0.81) is observed. The immunoprophylaxis with INH showed an efficacy of 95% (20/21); three (1.9%) patients developed active TB (spondylodiscitis, meningitis and lymphadenopathy) after the use of infliximab, reaffirming extrapulmonary involvement. These results suggest that PPD has a low sensitivity for detection of LTBI in RA and that the previous use of immunosuppressive drugs does not affect the response to PPD.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antirreumáticos/uso terapéutico , Tuberculosis Latente/diagnóstico , Tuberculosis Latente/epidemiología , Enfermedades Reumáticas/tratamiento farmacológico , Enfermedades Reumáticas/epidemiología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adulto , Antituberculosos/uso terapéutico , Artritis Psoriásica/tratamiento farmacológico , Artritis Psoriásica/epidemiología , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/epidemiología , Brasil , Comorbilidad , Femenino , Humanos , Infliximab , Isoniazida/uso terapéutico , Tuberculosis Latente/prevención & control , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Espondilitis Anquilosante/tratamiento farmacológico , Espondilitis Anquilosante/epidemiología , Tuberculina , Prueba de TuberculinaRESUMEN
OBJECTIVE: To identify tuberculosis infection in rheumatic patients on infliximab by use of PPD testing prior to immunobiologic therapy. METHODS: This study comprised 157 patients undergoing infliximab treatment and 734 other patients undergoing laboratory screening for tuberculosis infection originating from several services. The Mantoux technique was used for PPD testing, and an induration of at least 5 mm was considered reactive status. RESULTS: In the infliximab group, 13% of the patients reacted to PPD, while, in the other group, 27% of the patients reacted to PPD (χ² = 13; P = 0.0003). These patients were divided into categories: adults with chronic diseases, PPD reactivity of 22%; and other controls, PPD reactivity of 31%. This shows the heterogeneous response of that population (χ² = 7; P < 0.009). In the infliximab group, subdivided according to pathologies [rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PA)], different reactivity rates were observed, the lowest value occurring among RA patients: (RA x AS: OR = 0.13; CI: 0.03-0.47; χ ² = 12; P = 0.0004) and (RA x PA: OR = 0.16; CI: 0.02-1.04; χ² Yates corrected = 3.6; P = 0.05). The PPD reactivity in the RA subgroup (4%) was also lower as compared with that of the chronic patients group (22%) (OR = 0.16; CI: 0.05-0.49; χ² = 14; P = 0.0002), even when reclassified into four subgroups: rheumatology (OR = 0.19; CI: 0.04-0.72), kidney transplantation (OR = 0.16; CI: 0.05-0.51), infectology (OR = 0.21; CI: 0.05-0.75), and other conditions (OR = 0.13; CI: 0.04-0.44). CONCLUSION: The low prevalence of PPD reaction in this Brazilian population, mainly in chronic patients, with the worst performance among RA patients, showed that the test has limited value for diagnosis of tuberculosis infection in candidates to infliximab therapy.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antirreumáticos/uso terapéutico , Enfermedades Reumáticas/complicaciones , Enfermedades Reumáticas/tratamiento farmacológico , Prueba de Tuberculina , Tuberculosis/complicaciones , Tuberculosis/diagnóstico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adulto , Estudios Transversales , Femenino , Hospitales Generales , Humanos , Infliximab , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Tuberculosis/epidemiologíaRESUMEN
OBJETIVO: Identificar infecção tuberculosa em pacientes reumatológicos em uso de infliximabe, através do PPD realizado como pré-requisito ao início da terapia. MÉTODOS: Foram estudados 157 pacientes em uso de infliximabe e 734 outros pacientes sob triagem de infecção tuberculosa, procedentes de diversas clínicas. O PPD foi realizado pela técnica de Mantoux e considerado reator a partir de 5 mm. RESULTADOS: No grupo infliximabe, o PPD foi reator em 13 por cento e, entre os outros pacientes, a reatividade foi de 27 por cento (χ2 = 13; P = 0,0003). Estes foram subdivididos em adultos portadores de doenças crônicas, com 22 por cento de reatividade ao PPD e demais controles com 31 por cento de positividade, demonstrando heterogeneidade de resposta nessa população (χ2 = 7; P < 0,009). No grupo infliximabe, subdividido por patologias, Artrite Reumatoide (AR), EspondiliteAnquilosante (EA) eArtrite Psoriásica (AP), observaram-se reatividades dissemelhantes, sendo a reatividade na AR sempre menor (AR x EA: OR = 0,13; IC: 0,03-0,47; χ2 = 12; P = 0,0004) e (AR x AP: OR = 0,16; IC: 0,02-1,04; χ2corrigido de Yates = 3,6; P = 0,05). O PPD reator em AR (4 por cento) também foi menor quando comparado com o grupo dos usuários crônicos (22 por cento) (OR = 0,16; IC: 0,05-0,49; χ2 = 14; P = 0,0002), mesmo quando reclassificados em quatro subgrupos: reumatologia (OR = 0,19; IC: 0,04-0,72), transplante renal (OR = 0,16; IC: 0,05-0,51), infectologia (OR = 0,21; IC: 0,05-0,75) e outras clínicas (OR = 0,13; IC: 0,04-0,44). CONCLUSÃO: A baixa prevalência do PPD reativo nessa população brasileira, principalmente em pacientes crônicos, com pior desempenho em AR, mostrou que o teste tem valor limitado para o diagnóstico de infecção tuberculosa em candidatos à terapia com infliximabe.
OBJECTIVE: To identify tuberculosis infection in rheumatic patients on infliximab by use of PPD testing prior to immunobiologic therapy. METHODS: This study comprised 157 patients undergoing infliximab treatment and 734 other patients undergoing laboratory screening for tuberculosis infection originating from several services. The Mantoux technique was used for PPD testing, and an induration of at least 5 mm was considered reactive status. RESULTS: In the infliximab group, 13 percent of the patients reacted to PPD, while, in the other group, 27 percent of the patients reacted to PPD (χ2 = 13; P = 0.0003). These patients were divided into categories: adults with chronic diseases, PPD reactivity of 22 percent; and other controls, PPD reactivity of 31 percent. This shows the heterogeneous response of that population (χ2 = 7; P < 0.009). In the infliximab group, subdivided according to pathologies [rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PA)], different reactivity rates were observed, the lowest value occurring among RA patients: (RA x AS: OR = 0.13; CI: 0.03-0.47; χ2 = 12; P = 0.0004) and (RA x PA: OR = 0.16; CI: 0.02-1.04; χ2Yates corrected = 3.6; P = 0.05). The PPD reactivity in the RA subgroup (4 percent) was also lower as compared with that of the chronic patients group (22 percent) (OR = 0.16; CI: 0.05-0.49; χ2 = 14; P = 0.0002), even when reclassified into four subgroups: rheumatology (OR = 0.19; CI: 0.04-0.72), kidney transplantation (OR = 0.16; CI: 0.05-0.51), infectology (OR = 0.21; CI: 0.05-0.75), and other conditions (OR = 0.13; CI: 0.04-0.44). CONCLUSION: The low prevalence of PPD reaction in this Brazilian population, mainly in chronic patients, with the worst performance among RA patients, shwoed that the test has limited value for diagnosis of tuberculosis infection in candidates to infliximab therapy.
Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Anticuerpos Monoclonales/uso terapéutico , Antirreumáticos/uso terapéutico , Enfermedades Reumáticas/complicaciones , Enfermedades Reumáticas/tratamiento farmacológico , Prueba de Tuberculina , Tuberculosis/complicaciones , Tuberculosis/diagnóstico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Estudios Transversales , Hospitales Generales , Prevalencia , Estudios Retrospectivos , Tuberculosis/epidemiologíaRESUMEN
OBJECTIVES: To describe the initial clinical manifestations of Wegener's Granulomatosis (WG) in Brazil. PATIENTS AND METHODS: Retrospective analysis of six medical records of WG patients followed-up at the Rheumatology Department of Hospital Geral of Fortaleza (HGF), as well as a bibliographic survey of cases of WG in Brazil on LILACS, SciELO, and MEDLINE databases. RESULTS: The study identified 49 patients, 15 (31%) males and 34 (69%) females. Systemic disease was observed in 35 patients (73%): 28 adults, 5 children, and 2 teenagers. Limited disease was observed in 13 adults and 1 child. The average age of onset in adults was 42.2 years (18 to 65 years). Acute clinical manifestations, with the onset of symptoms less than three months before the diagnosis, were observed in 41% (20/49) of the patients, and the insidious presentation in 59% (29/49) of the patients. The prevalence of the initial clinical manifestations in adults with systemic disease (n = 28) was 64% (18/28), upper airways, 36% (10/28), lungs, 18% (5/28), kidneys, 25% (7/28), eyes, 11% (3/28) skin, 25% (7/28), musculoskeletal, and 7% (2/28), neurological. In adults (n = 13) with limited disease, prevalent symptoms included: upper airway, 84% (10/13), eyes, 23% (3/13), and lungs, 15% (2/13). CONCLUSION: The prevalence of the initial clinical manifestations of WG in Brazil was similar to that reported in the literature. The lack of specific symptoms may delay diagnosis cases with insidious presentation of the disease and increase the morbidity and mortality in acute disease.
Asunto(s)
Granulomatosis con Poliangitis/diagnóstico , Adolescente , Adulto , Estudios Transversales , Femenino , Granulomatosis con Poliangitis/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto JovenRESUMEN
Amyloidosis is a heterogeneous group of diseases characterized by extracellular deposits of a material composed of aggregates of amyloid--a poorly coupled protein--far from the site of synthesis, causing target organ dysfunction and clinical disease. Systemic amyloidosis A (AA), secondary to infections and chronic inflammation, especially rheumatoid arthritis (RA), is the most common form of amyloid deposition. Treatment of AA consists in the control or resolution of the baseline condition. The objective of the present study was to report a case of secondary renal amyloidosis in a patient with long-term refractory RA who presented sustained clinical improvement after the use of anti-TNFα (etanercept).
Asunto(s)
Amiloidosis/tratamiento farmacológico , Amiloidosis/etiología , Artritis Reumatoide/complicaciones , Inmunoglobulina G/uso terapéutico , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/etiología , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Anciano , Etanercept , Femenino , HumanosRESUMEN
As amiloidoses são um grupo heterogêneo de doenças caracterizadas pelo depósito extracelular de uma substância amiloide composta por agregados de proteínas mal acopladas que se depositam longe do sítio de síntese, causando disfunção do órgão-alvo e doença clínica. A forma sistêmica mais comum é a amiloidose A (AA) secundária às infecções e às inflamações crônicas, sendo a artrite reumatoide (AR) a causa mais frequente. O tratamento da amiloidose AA consiste no controle ou na resolução da doença de base. O objetivo do presente estudo é relatar um caso de amiloidose renal secundária em paciente com AR refratária de longa duração que apresentou melhora clínica sustentada após o uso de anti-TNFα (etanercepte).
Amyloidosis is a heterogeneous group of diseases characterized by extracellular deposits of a material composed of aggregates of amyloid - a poorly coupled protein - far from the site of synthesis, causing target organ dysfunction and clinical disease. Systemic amyloidosis A (AA), secondary to infections and chronic inflammation, especially rheumatoid arthritis (RA), is the most common form of amyloid deposition. Treatment of AA consists in the control or resolution of the baseline condition. The objective of the present study was to report a case of secondary renal amyloidosis in a patient with long-term refractory RA who presented sustained clinical improvement after the use of anti-TNFα (etanercept).
Asunto(s)
Anciano , Femenino , Humanos , Amiloidosis/tratamiento farmacológico , Amiloidosis/etiología , Artritis Reumatoide/complicaciones , Inmunoglobulina G/uso terapéutico , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/etiología , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidoresRESUMEN
OBJETIVOS: Descrever as manifestações clínicas iniciais da Granulomatose de Wegener (GW) diagnosticada no Brasil. PACIENTES E MÉTODOS: Análise retrospectiva de seis prontuários do Serviço de Reumatologia do Hospital Geral de Fortaleza (HGF), assim como a realização de um levantamento bibliográfico dos casos de GW descritos no Brasil obtidos dos bancos de dados LILACS, SciELO e MEDLINE. RESULTADOS: O estudo identificou 49 pacientes; 15 (31 por cento) do sexo masculino e 34 (69 por cento) do sexo feminino. A forma sistêmica ocorreu em 35 pacientes (73 por cento): 28 adultos, cinco crianças e dois adolescentes. A doença limitada ocorreu em 13 adultos e uma criança. A média da idade adulta no início da doença foi de 42,2 anos (18 a 65 anos). O quadro clínico agudo, com sintomas há menos de três meses do diagnóstico, ocorreu em 41 por cento (20/49) da casuística e a forma insidiosa, em 59 por cento (29/49) dos pacientes. A prevalência das manifestações clínicas iniciais nos adultos com doença sistêmica (n = 28) foi 64 por cento (18/28) das vias aéreas superiores (VAS), 36 por cento (10/28) pulmonares, 18 por cento (5/28) renais, 25 por cento (7/28) oculares, 11 por cento (3/28) cutâneas, 25 por cento (7/28) musculoesqueléticas e 7 por cento (2/28) neurológicas. Na forma limitada do adulto (n = 13), os sintomas prevalentes foram 84 por cento (11/13) VAS, 23 por cento (3/13) oculares e 15 por cento (2/13) pulmonares. CONCLUSÃO: No Brasil, a prevalência das manifestações clínicas iniciais da GW foi semelhante aos resultados da literatura. A falta de especificidade dos sintomas pode retardar o diagnóstico na forma insidiosa da doença e aumentar a morbimortalidade das formas agudas.
OBJECTIVES: To describe the initial clinical manifestations of Wegener's Granulomatosis (WG) in Brazil. PATIENTS AND METHODS: Retrospective analysis of six medical records of WG patients followed-up at the Rheumatology Department of Hospital Geral of Fortaleza (HGF), as well as a bibliographic survey of cases of WG in Brazil on LILACS, SciELO, and MEDLINE databases. RESULTS: The study identified 49 patients, 15 (31 percent) males and 34 (69 percent) females. Systemic disease was observed in 35 patients (73 percent): 28 adults, 5 children, and 2 teenagers. Limited disease was observed in 13 adults and 1 child. The average age of onset in adults was 42.2 years (18 to 65 years). Acute clinical manifestations, with the onset of symptoms less than three months before the diagnosis, were observed in 41 percent (20/49) of the patients, and the insidious presentation in 59 percent (29/49) of the patients. The prevalence of the initial clinical manifestations in adults with systemic disease (n = 28) was 64 percent (18/28), upper airways, 36 percent (10/28), lungs, 18 percent (5/28), kidneys, 25 percent (7/28), eyes, 11 percent (3/28) skin, 25 percent (7/28), musculoskeletal, and 7 percent (2/28), neurological. In adults (n = 13) with limited disease, prevalent symptoms included: upper airway, 84 percent (10/13), eyes, 23 percent (3/13), and lungs, 15 percent (2/13). CONCLUSION: The prevalence of the initial clinical manifestations of WG in Brazil was similar to that reported in the literature. The lack of specific symptoms may delay diagnosis cases with insidious presentation of the disease and increase the morbidity and mortality in acute disease.
Asunto(s)
Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Granulomatosis con Poliangitis/diagnóstico , Estudios Transversales , Estudios Retrospectivos , Granulomatosis con Poliangitis/complicacionesRESUMEN
A retinite por citomegalovírus (CMV) é uma doença rara que acomete principalmente pacientes com a síndrome da imunodeficiência adquirida (AIDS). No entanto, outros pacientes imunossuprimidos, como os transplantados, os que estão em uso de quimioterápicos, pacientes com lúpus eritematoso sistêmico (LES) ou em tratamento com drogas imunossupressoras também podem ser acometidos. O quadro clínico caracteriza-se por visão turva, diminuição da acuidade ou alterações de campo visual, geralmente unilateral, podendo ocorrer deslocamento de retina. A perda visual é progressiva, evolui em ritmo variável até a completa amaurose do olho acometido. O presente relato de caso descreve um paciente com vasculite leucocitoclástica grave submetido à terapia com corticoide em dose imunossupressora que evoluiu com glaucoma, panuveíte por CMV, perda da acuidade visual e infecção bacteriana secundária.
Cytomegalovirus (CMV) retinitis is a rare disease which mainly affects patients with acquired immunodeficiency syndrome (AIDS). Nevertheless, other immunosuppressed patients, such as the organ transplant recipients, the ones using chemotherapy, patients with systemic lupus erythematosus (SLE) or in treatment with immunosuppressive drugs can also be attacked. The clinical characteristics are blurred vision, decrease of the visual acuity or visual field alterations, generally unilateral, with the possibility of retinal detachment. The visual loss is progressive, evolving in a variable rate until complete amaurosis of the attacked eye. The present case report describes a patient with severe leukocytoclastic vasculitis, submitted to corticosteroid therapy in immunosuppressive doses that evolved with glaucoma, panuveitis by CMV, loss of visual acuity and secondary bacterial infection.